MX2022003149A - Proteinas heterodimericas. - Google Patents

Proteinas heterodimericas.

Info

Publication number
MX2022003149A
MX2022003149A MX2022003149A MX2022003149A MX2022003149A MX 2022003149 A MX2022003149 A MX 2022003149A MX 2022003149 A MX2022003149 A MX 2022003149A MX 2022003149 A MX2022003149 A MX 2022003149A MX 2022003149 A MX2022003149 A MX 2022003149A
Authority
MX
Mexico
Prior art keywords
heterodimeric proteins
proteins
heterodimeric
multispecific
antibodies
Prior art date
Application number
MX2022003149A
Other languages
English (en)
Spanish (es)
Inventor
Veronica Franciszka Ilkow
Zahra Jawad
Dhan Sidhartha Chand
Original Assignee
Agenus Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agenus Inc filed Critical Agenus Inc
Publication of MX2022003149A publication Critical patent/MX2022003149A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MX2022003149A 2019-09-27 2020-09-28 Proteinas heterodimericas. MX2022003149A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962906918P 2019-09-27 2019-09-27
PCT/US2020/053114 WO2021062382A1 (en) 2019-09-27 2020-09-28 Heterodimeric proteins

Publications (1)

Publication Number Publication Date
MX2022003149A true MX2022003149A (es) 2022-04-06

Family

ID=75166489

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022003149A MX2022003149A (es) 2019-09-27 2020-09-28 Proteinas heterodimericas.

Country Status (10)

Country Link
US (2) US20210130495A1 (enExample)
EP (1) EP4034570A4 (enExample)
JP (1) JP7842011B2 (enExample)
KR (1) KR20220069935A (enExample)
CN (1) CN114787186B (enExample)
AU (1) AU2020355253A1 (enExample)
BR (1) BR112022004789A2 (enExample)
IL (1) IL291618A (enExample)
MX (1) MX2022003149A (enExample)
WO (1) WO2021062382A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190016802A1 (en) 2017-07-14 2019-01-17 Immatics Biotechnologies Gmbh Dual specificity polypeptide molecule
WO2022233956A1 (en) 2021-05-05 2022-11-10 Immatics Biotechnologies Gmbh Antigen binding proteins specifically binding prame

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0979281B1 (en) * 1997-05-02 2005-07-20 Genentech, Inc. A method for making multispecific antibodies having heteromultimeric and common components
US8093357B2 (en) * 2002-03-01 2012-01-10 Xencor, Inc. Optimized Fc variants and methods for their generation
WO2005047327A2 (en) * 2003-11-12 2005-05-26 Biogen Idec Ma Inc. NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO
TW201302793A (zh) * 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
US10689447B2 (en) 2011-02-04 2020-06-23 Genentech, Inc. Fc variants and methods for their production
WO2013033008A2 (en) * 2011-08-26 2013-03-07 Merrimack Pharmaceuticals, Inc. Tandem fc bispecific antibodies
US9574010B2 (en) * 2011-11-04 2017-02-21 Zymeworks Inc. Stable heterodimeric antibody design with mutations in the Fc domain
CN105102618B (zh) * 2012-12-27 2018-04-17 中外制药株式会社 异源二聚化多肽
MX2019004327A (es) * 2016-10-14 2019-10-14 Xencor Inc Proteinas de fusion heterodimericas biespecificas que contienen proteinas de fusion fc il-15/il-15ra y fragmentos de anticuerpo pd-1.
KR20200014379A (ko) * 2017-06-05 2020-02-10 얀센 바이오테크 인코포레이티드 비대칭 ch2-ch3 영역 돌연변이를 갖는 조작된 다중특이성 항체 및 다른 다량체 단백질
CN110028584B (zh) 2018-01-12 2021-04-06 北京科昕生物科技有限公司 针对egfr蛋白和met蛋白的双特异性抗体
KR20210080460A (ko) * 2018-10-23 2021-06-30 드래곤플라이 쎄라퓨틱스, 인크. 이종이량체성 Fc-융합된 단백질

Also Published As

Publication number Publication date
IL291618A (en) 2022-05-01
JP7842011B2 (ja) 2026-04-07
EP4034570A1 (en) 2022-08-03
WO2021062382A1 (en) 2021-04-01
CA3151574A1 (en) 2021-04-01
BR112022004789A2 (pt) 2022-06-21
KR20220069935A (ko) 2022-05-27
US20210130495A1 (en) 2021-05-06
CN114787186A (zh) 2022-07-22
JP2022549351A (ja) 2022-11-24
EP4034570A4 (en) 2023-10-25
CN114787186B (zh) 2025-06-03
AU2020355253A1 (en) 2022-03-24
US20240360249A1 (en) 2024-10-31

Similar Documents

Publication Publication Date Title
JOP20200313A1 (ar) أجسام مضادة dll3-cd3 ثنائية الخاصية
WO2019173692A3 (en) Anti-cd73 antibodies and methods of use thereof
SA520411173B1 (ar) Pd-l1 عوامل ربط ترتبط بـ واستخدامها cd137
MX2019012223A (es) Anticuerpos anti-cd137 y metodos de uso de los mismos.
WO2018132739A3 (en) T cell receptors that bind to ny-eso-1 and methods of use thereof
MX2024003535A (es) Proteina mutante de interleucina-2 y fusion de la misma.
CR20200471A (es) PÉPTIDOS Y COMBINACIÒN DE PÉPTIDOS NOVEDOSOS PARA SU USO EN INMUNOTERAPIA CONTRA DIVERSOS TUMORES (Divisional 2017-0522)
EA202090562A1 (ru) Связывающие gpcr белки и их синтез
EP3812398A3 (en) Anti-cd3 antibodies, anti-cd123 antibodies and bispecific antibodies specifically binding to cd3 and/or cd123
MX395287B (es) Nuevos receptores de linfocitos t e inmunoterapia basada en el uso de los mismos.
EA201792484A1 (ru) Новые клеточные эпитопы и комбинации клеточных эпитопов для применения в иммунотерапии миеломы и других видов рака
UY31533A1 (es) Moleculas de enlace al receptor humano ox40
BR122020002986A8 (pt) Método e composições para imunoterapia celular
BR112017010110A2 (pt) anticorpos contra cd73 e usos do mesmo
MY162737A (en) 4-1bb binding molecules
EA201270713A1 (ru) Белки на основе фибронектина с каркасными доменами, которые связывают ил-23
BR112019004711A2 (pt) receptores de antígeno quiméricos compreendendo domínios de fibronectina tipo iii específicos para bcma e usos dos mesmos
CL2017002407A1 (es) Péptidos y combinación de péptidos novedosos para su uso en inmunoterapia contra diversos tumores
EA201991409A3 (ru) Антитела к ингибитору активатора плазминогена 1 (pai-1) и пути их применения
ZA202201464B (en) Anti-tigit antibodies and application thereof
BR112022003740A2 (pt) Anticorpos anti-cd96 e métodos de uso dos mesmos
WO2020070678A3 (en) Antibodies specific for human and cynomolgus apoc3 and methods of use thereof
BR112022004789A2 (pt) Proteínas heterodiméricas
BR112023022367A2 (pt) Anticorpos anti-tigit e métodos de uso dos mesmos
MX2025000487A (es) Anticuerpos anti-mesotelina